Welcome to LookChem.com Sign In|Join Free

CAS

  • or

78879-20-6

Post Buying Request

78879-20-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

78879-20-6 Usage

Uses

Boc-Tic-OH, is an amino acid building block used in peptide synthesis. With a growing peptide drug market the fast, reliable synthesis of peptides is of great importance.

Check Digit Verification of cas no

The CAS Registry Mumber 78879-20-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,8,8,7 and 9 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 78879-20:
(7*7)+(6*8)+(5*8)+(4*7)+(3*9)+(2*2)+(1*0)=196
196 % 10 = 6
So 78879-20-6 is a valid CAS Registry Number.
InChI:InChI=1/C15H19NO4/c1-15(2,3)20-14(19)16-9-11-7-5-4-6-10(11)8-12(16)13(17)18/h4-7,12H,8-9H2,1-3H3,(H,17,18)/p-1/t12-/m0/s1

78879-20-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (B4501)  (S)-2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid  >98.0%(HPLC)(T)

  • 78879-20-6

  • 5g

  • 690.00CNY

  • Detail
  • TCI America

  • (B4501)  (S)-2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic Acid  >98.0%(HPLC)(T)

  • 78879-20-6

  • 25g

  • 2,390.00CNY

  • Detail
  • Alfa Aesar

  • (H61423)  (S)-N-Boc-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 98%   

  • 78879-20-6

  • 250mg

  • 417.0CNY

  • Detail
  • Alfa Aesar

  • (H61423)  (S)-N-Boc-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 98%   

  • 78879-20-6

  • 1g

  • 1499.0CNY

  • Detail
  • Alfa Aesar

  • (H61423)  (S)-N-Boc-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 98%   

  • 78879-20-6

  • 5g

  • 5184.0CNY

  • Detail
  • Aldrich

  • (15504)  Boc-Tic-OH  ≥97.0% (TLC)

  • 78879-20-6

  • 15504-1G-F

  • 2,136.42CNY

  • Detail

78879-20-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name Boc-(S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

1.2 Other means of identification

Product number -
Other names N-Boc-(L)-Tic

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:78879-20-6 SDS

78879-20-6Relevant articles and documents

Cyclic formyl and cyclic ketone compounds as well as preparation method and pharmaceutical application thereof

-

Paragraph 0035; 0066-0067; 0070, (2020/08/27)

The invention discloses cyclic formyl and cyclic ketone compounds as well as a preparation method and a pharmaceutical application thereof. The compound shown in (I) has a good function of inhibitinginfection and replication of Zika viruses and dengue vir

Neuroligin-2-derived peptide-covered polyamidoamine-based (PAMAM) dendrimers enhance pancreatic β-cells' proliferation and functions

Munder, Anna,Moskovitz, Yoni,Meir, Aviv,Kahremany, Shirin,Levy, Laura,Kolitz-Domb, Michal,Cohen, Guy,Shtriker, Efrat,Viskind, Olga,Lellouche, Jean-Paul,Senderowitz, Hanoch,Chessler, Steven D.,Korshin, Edward E.,Ruthstein, Sharon,Gruzman, Arie

, p. 280 - 293 (2019/03/02)

Pancreatic β-cell membranes and presynaptic areas of neurons contain analogous protein complexes that control the secretion of bioactive molecules. These complexes include the neuroligins (NLs) and their binding partners, the neurexins (NXs). It has been recently reported that both insulin secretion and the proliferation rates of β-cells increase when cells are co-cultured with full-length NL-2 clusters. The pharmacological use of full-length protein is always problematic due to its unfavorable pharmacokinetic properties. Thus, NL-2-derived short peptide was conjugated to the surface of polyamidoamine-based (PAMAM) dendrimers. This nanoscale composite improved β-cell functions in terms of the rate of proliferation, glucose-stimulated insulin secretion (GSIS), and functional maturation. This functionalized dendrimer also protected β-cells under cellular stress conditions. In addition, various novel peptidomimetic scaffolds of NL-2-derived peptide were designed, synthesized, and conjugated to the surface of PAMAM in order to increase the biostability of the conjugates. However, after being covered by peptidomimetics, PAMAM dendrimers were inactive. Thus, the original peptide-based PAMAM dendrimer is a leading compound for continued research that might provide a unique starting point for designing an innovative class of antidiabetic therapeutics that possess a unique mode of action.

Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA

Wu, Jianhui,Zhu, Haimei,Yang, Guodong,He, Jianhong,Wang, Yuji,Zhao, Shurui,Zhang, Xiaoyi,Gui, Lin,Zhao, Ming,Peng, Shiqi

, p. 1139 - 1158 (2018/03/09)

Background: Arterial thrombosis has been associated with a series of pathological conditions, and the discovery of arterial thrombosis inhibitor is of clinical importance. Methods: By analyzing the pharmacophores of anti-platelet agents, thrombus targeting peptide and anti-thrombotic nano-systems 3S-1,2,3,4-tetrahydroisoquino- line-3-carbonyl-Thr-Ala- Arg-Gly-Asp(Val)-Val (IQCA-TAVV) was designed and prepared as a nano-scaled arterial thrombosis inhibitor. Results: In vitro the nanoparticles of IQCA-TAVV were able to adhere onto the surface of activated platelets, attenuate activated platelets to extend pseudopodia and inhibit activated platelets to form aggregators. In vivo IQCA-TAVV targeted arterial thrombus, dose depend- ently inhibited arterial thrombosis with a 1 nmol/kg of minimal effective dose, and the activity was ~1670 folds of that of aspirin. Conclusion: IQCA-TAVV represented the design, preparation and application of nanomedicine capable of adhering on the surface of activated platelets, attenuating platelet activation, targeting arterial thrombus and inhibiting arterial thrombosis.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 78879-20-6